U.S. Cancer Contrast Media Market Size – By Product Type (Gadolinium-based Contrast Media, Iodinated Contrast Media), Modality (Nuclear Imaging, CT, MRI, Mammography), Application (Breast Cancer, Bladder Cancer, Lung Cancer), End-use & Forecast, 2024 – 2032

U.S. Cancer Contrast Media Market Size – By Product Type (Gadolinium-based Contrast Media, Iodinated Contrast Media), Modality (Nuclear Imaging, CT, MRI, Mammography), Application (Breast Cancer, Bladder Cancer, Lung Cancer), End-use & Forecast, 2024 – 2032

U.S. Cancer Contrast Media Market Size

U.S. Cancer Contrast Media Market size was valued at USD 2.4 billion in 2023 and is estimated to grow at a CAGR of 4.9% between 2024 and 2032. Cancer contrast media refers to specialized contrast agents or dyes used in medical imaging procedures specifically aimed at diagnosing, staging, or monitoring cancer. These contrast media are designed to enhance the visualization of cancerous tissues, tumors, and associated structures during imaging studies such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound.
 

The increasing prevalence of cancer cases has emerged as a significant driver for the market. For instance, according to the American Cancer Society in 2021, there were an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the U.S. Therefore, there is a rising need for effective treatments such as chemotherapy, radiation therapy, immunotherapy to address the complexities of managing cancer-related issues.
 

Furthermore, growing technological advancements in cancer contrast imaging such as MRI contrast media, which is set to reach USD 2.5 billion by 2032, increasing number of clinical studies, among other contributing factors are anticipated to propel the industry growth.
 

U.S. Cancer Contrast Media Market Trends

Technological advancements in cancer contrast media have revolutionized the field of oncology by significantly improving the accuracy and efficacy of cancer diagnosis, staging, and treatment monitoring.
 

• Significant progress has been made in designing and formulating contrast agents, resulting in versions that exhibit heightened specificity for cancerous tissues. These advanced agents have the capability to target biomarkers or receptors that are overexpressed in cancer cells.
   
• Furthermore, advances in imaging modalities such as MRI and CT scanner have enabled multiparametric imaging techniques. These techniques combine different imaging sequences or modalities along with the use of multiple contrast agents to provide comprehensive information about tumor biology, including its microenvironment, vascularity, and metabolic activity.
   

U.S. Cancer Contrast Media Market Analysis

Based on product type, the market is classified into gadolinium-based contrast media, iodinated contrast media, radioactive agents, and other product types. The iodinated contrast media segment held over 1.4 billion revenue in 2023.
 

• Iodinated contrast media plays a valuable role in cancer imaging by enhancing the visibility of tumors and surrounding tissues during diagnostic imaging procedures. This improved visualization allows for more accurate detection, characterization, and staging of cancerous lesions.
   
• Furthermore, iodinated contrast agents can be used with various imaging modalities, including computed tomography scans and angiography, making them versatile tools for cancer diagnosis and staging.
   
• Moreover, iodinated contrast media are rapidly cleared from the body through renal excretion, minimizing the risk of prolonged exposure and potential toxicity, thereby fostering the segmental growth.

Based on modality, the U.S. cancer contrast media market is bifurcated into nuclear imaging, CT scan, mammography, MRI scan, and ultrasound. The CT scan segment is poised to cross USD 1.2 billion by the end of 2032.
 

• Contrast-enhanced CT scan provides better visualization of blood vessels and tissues, making it easier to identify tumors, metastases, and abnormalities within the body.
   
• Further, by enhancing the contrast between tumors and surrounding tissues, CT scan with contrast enables accurate staging of cancer, helping clinicians determine the extent of disease spread and plan appropriate treatment strategies.
   
• Moreover, contrast-enhanced CT scan serves as valuable tools for monitoring the response to cancer treatment longitudinally. Variations in tumor size provide detailed insights into treatment efficacy and progression, thereby augmenting the segmental growth of the market.
   

Based on application, the market is segmented into breast cancer, bladder cancer, colorectal cancer, lung cancer, prostate cancer, and other applications. The breast cancer segment accounted for 24.1% of the market share in 2023.
 

• Breast cancer originates in the cells of the breast. It occurs when abnormal cells in the breast tissue begin to grow and divide uncontrollably, forming a mass or tumor.
   
• Growing prevalence of breast cancer is estimated to augment market growth. For instance, according to the National Breast Cancer Foundation, in 2023, it was estimated that approximately 297,790 women were diagnosed with invasive breast cancer in U.S.
   
• Further, contrast media can provide additional information about the vascularity and perfusion of breast lesions. This helps in distinguishing between benign and malignant tumors and assessing tumor aggressiveness, aiding in treatment planning decisions. Thus, all these factors are escalating the segmental growth.
   

Based on end-use, the U.S. cancer contrast media market is categorized into hospitals, specialty clinics, diagnostics laboratories, and other end-users. The hospitals segment held over USD 677.2 million revenue size in 2023.
 

• Contrast media enhances the visibility of tumors and aids in distinguishing between cancerous and non-cancerous tissues. This leads to more accurate diagnosis, enabling healthcare providers to initiate appropriate treatment plans promptly.
   
• Further, contrast-enhanced imaging helps surgeons to visualize tumors during procedures more clearly, allowing for more accurate tumor resection while minimizing damage to healthy surrounding tissues.
   
• Thus, the use of cancer contrast media in hospitals contributes to better patient care, improved treatment outcomes, streamlined workflows, and a competitive edge in the healthcare market, thereby contributing to the growth of the market.

U.S. cancer contrast media market size recorded around USD 2.4 billion in 2023.
 

• The region has a large population, with an increasing prevalence of cancer cases, and a growing number of clinical studies which play a crucial role in driving innovation and shaping the future of cancer treatment.
   
• For instance, according to the National Cancer Institute, in 2023, approximately two million individuals were diagnosed with cancer in the U.S.
   
• Further, U.S. is at the forefront of technological advancements in cancer contrast imaging including the development of more precise imaging modalities and the refinement of contrast agents for improved tumor visualization and characterization.
   
• Thus, the underlying factors are projected to expand the market's growth.
   

U.S. Cancer Contrast Media Market Share

The U.S. cancer contrast media industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced devices based on different technologies is among a key market strategy.
 

U.S. Cancer Contrast Media Market Companies

Some of the eminent market participants operating in the U.S. cancer contrast media industry include

• Bayer AG
• Bracco Imaging S.p.A.
• GE Healthcare Technologies Inc
• Guerbet
• iMAX Diagnostic Imaging
• Lantheus Medical Imaging
• nanoPET Pharma GmbH
• Subtle Medical, Inc.
• Telix Pharmaceuticals Limited
• Trivitron Healthcare
   

U.S. Cancer Contrast Media Industry News

• In February 2023, Guerbet announced the commercial launch and dosing of Elucirem (gadopiclenol) injection after obtaining FDA approval. Elucirem, a next-generation GBCA, offered exceptional stability as a macrocyclic gadolinium-based contrast agent. This development significantly bolstered Guerbet's position in the market, enhancing its product portfolio and reinforcing its reputation as a leader in medical imaging.
   
• In September 2023, Bayer and Hologic, Inc., unveiled an international partnership aimed at providing contrast-enhanced mammography (CEM) solutions to enhance breast cancer detection across various countries including Canada, Europe, and the Asia Pacific regions. This collaboration benefited both companies by leveraging their respective expertise and technologies to address a critical need in breast cancer diagnostics.
   

The United States cancer contrast media market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments

Click here to Buy Section of this Report

Market, By Product Type

• Gadolinium-based contrast media   
• Iodinated contrast media      
• Radioactive agents
• Other product types

Market, By Modality

• Nuclear imaging
• CT scan
• Mammography
• MRI scan
• Ultrasound

Market, By Application

• Breast cancer
• Bladder cancer
• Colorectal cancer
• Lung cancer
• Prostate cancer
• Other applications

Market, By End-use

• Hospitals
• Specialty clinics
• Diagnostic centers
• Other end-users